Fiche société
Aurinia Pharmaceuticals Inc.
Traitements, essais et publications liés.
Traitements6programmes
Essais2liés
Publications5liées
SourceDBlocale
Traitements
6| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| AritinerceptThis clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept. | Myasthénie | Phase 1/2 | À vérifier | United States | À vérifier |
| belimumab, obinutuzumab or anifrolumabThe goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN). | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| LUPKYNISThe goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN). | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| mycophenolic acid analog (MPAA)The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN). | Lupus | Phase 4 | À vérifier | United States | À vérifier |
| AritinerceptThis clinical study will enroll patients with generalized myasthenia gravis (gMG). The goal of this clinical study is to assess the safety, tolerability, effectiveness, pharmacokinetics (how the body processes the drug) and pharmacodynamics (how the drug affects the body) of aritinercept. | Myasthénie | Phase 1/2 | À vérifier | United States | À vérifier |
| LUPKYNISThe goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN). | Lupus | Phase 4 | À vérifier | United States | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| LUPKYNIS | Lupus | Phase 4 | NCT07611214 | PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | RECRUITING |
| Aritinercept | Myasthénie | Phase 1/2 | NCT07596901 | Study of Aritinercept in Patients With Generalized Myasthenia Gravis | RECRUITING |
Publications
5| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| mycophenolic acid analog (MPAA) | Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. | Clinical kidney journal | ||
| LUPKYNIS | Voclosporin: A Novel Calcineurin Inhibitor for the Treatment of Lupus Nephritis. | The Annals of pharmacotherapy | ||
| mycophenolic acid analog (MPAA) | Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups. | Lupus science & medicine | ||
| mycophenolic acid analog (MPAA) | Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis. | Kidney international reports | ||
| LUPKYNIS | Obinutuzumab (Gazyva) for lupus nephritis. | The Medical letter on drugs and therapeutics |